SULLIVAN GREGORY M 4

What Happened

• Gregory M. Sullivan, Chief Medical Officer of Tonix Pharmaceuticals (TNXP), was granted two derivative awards on 2026-02-24: 39,012 shares and 39,011 shares, for a combined total of 78,023 shares. The reported price for each award is $0.00, and the filing lists these as derivative awards (options) rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-02-24; filing date: 2026-02-26 (filed timely).
• Awards: 39,012 shares and 39,011 shares; reported price $0.00; total awarded = 78,023 derivative shares.
• Shares owned after the transaction: not specified in the provided data.
• Footnotes: (1) One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. (2) The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.
• No indication this was a sale, tax-withholding, or 10b5-1 plan.

Context

• These entries reflect equity awards (derivative option grants) as long-term compensation — no cash changed hands at grant. Vesting conditions apply, so the shares/options are not immediately liquid. Such grants are routine for executive compensation and do not by themselves indicate imminent buying or selling of stock.